The $125M milestone provides near-term cash visibility for Novavax, which has a $1.7B market cap. Monitor Sanofi's Phase 3 trial progress and the manufacturing tech transfer milestone (mid-2027) as the next catalysts. The $225M U.S. launch milestone is contingent on clinical and regulatory success, which carries execution risk.
Price Chart
Executive Summary
Novavax announced that Sanofi dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial, triggering a $125 million milestone payment under their collaboration agreement. The payment is expected by Q1 2027. The partnership has generated over $1 billion in revenue for Novavax to date, and additional milestones of $75 million (manufacturing tech transfer, mid-2027) and $225 million (U.S. launch of combination vaccine) remain achievable.
Key Facts
- Sanofi dosed fifth patient in Phase 3 influenza-COVID-19 combination vaccine trial in the EU on October 28, 2026
- Fifth patient dosing triggered a $125 million milestone payment from Sanofi to Novavax
- Payment anticipated by Q1 2027
- Partnership has generated over $1 billion in revenue for Novavax through 6/30/2026 plus this milestone
- Additional $75 million milestone upon successful manufacturing tech transfer (mid-2027)
- Additional $225 million milestone upon U.S. launch of combination vaccine after clinical and regulatory requirements
- Novavax eligible for royalties on Sanofi sales of Nuvaxovid and combination products
- Global flu and COVID-19 combined market exceeds $10 billion
Financial Impact
$125 million milestone payment triggered, expected by Q1 2027; additional potential milestones of $75M and $225M
Risk Factors
- Payment expected by Q1 2027, not immediate
- Phase 3 trial may fail or be delayed, impacting future milestones
- U.S. regulatory requirements may differ from EU, creating uncertainty for the $225M milestone
- Novavax depends on Serum Institute for co-formulation and filling, which could cause supply disruptions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-120221 |
| Document: tm2628546d1_ex99-1.htm | 0001104659-26-120221 |
| Document: 0001104659-26-120221-index-headers.html | 0001104659-26-120221 |
| Document: 0001104659-26-120221-index.html | 0001104659-26-120221 |
| Document: 0001104659-26-120221.txt | 0001104659-26-120221 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $10.19 | awaiting T+5 | awaiting T+5 | $10.08 (−1.08%) |
Oct 16, 2026 16d ago | SC 13G | $10.82 $9.40 | ▼ −13.12% | ▼ −12.98% | $10.08 (−6.84%) |
Oct 16, 2026 16d ago | SC 13D/A | $10.82 $9.40 | ▲ +13.12% | ▲ +12.98% | $10.08 (+6.84%) |
Aug 6, 2026 12w ago | 8-K | $7.74 $8.14 | ▲ +5.17% | ▲ +3.96% | $10.08 (+30.23%) |
May 6, 2026 25w ago | 8-K | $9.36 $9.62 | ▲ +2.78% | ▲ +1.65% | $10.08 (+7.69%) |
Apr 27, 2026 26w ago | DEFA14A | $8.07 $8.03 | ▼ −0.50% | ▼ −0.90% | $10.08 (+24.91%) |
Feb 26, 2026 35w ago | 8-K | $11.19 $9.99 | ▼ −10.72% | ▼ −9.60% | $10.08 (−9.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers